Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis
Open Access
- 6 December 2017
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 15 (1) , 237
Abstract
To assess the reliability, validity, and responsiveness to treatment change of the single-item measure, Severity of Worst Tiredness, in patients with rheumatoid arthritis (RA). Data from two Phase 3, randomized, placebo-controlled (RA-BUILD; and active-controlled [RA-BEAM]), clinical studies of the efficacy of baricitinib in adults with moderately to severely active RA were used. The psychometric properties of the single-item measure, Severity of Worst Tiredness, were assessed, including test-retest reliability, convergent and discriminant validity, known-groups validity, and responsiveness, using other patient- and clinician-reported outcomes frequently assessed in RA patients. Test-retest reliability of the Severity of Worst Tiredness was supported through large intraclass correlation coefficients (0.89 ≤ ICC ≤ 0.91). Moderate-to-large correlations were observed between this patient-reported outcome (PRO) and other related patient- and clinician-reported assessments of RA symptoms and patient functioning, supporting construct validity of the measure (│r│ ≥ 0.41). The instrument also displayed known-groups validity through statistically significant differences between mean values of the Severity of Worst Tiredness defined using other indicators of RA severity. Finally, responsiveness was supported by large and statistically significant differences in change scores from Day 1 to Week 12 for patients comparing responders and nonresponders using the American College of Rheumatology 20 (ACR20) criteria. The Severity of Worst Tiredness PRO demonstrated adequate reliability, validity, and responsiveness in clinical trials of adults with moderately to severely active RA and is fit for purpose in this patient population.Keywords
Funding Information
- Eli Lilly and Company
- Incyte Corporation
This publication has 33 references indexed in Scilit:
- A Multidimensional Model of Fatigue in Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2012
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical TrialsAnnals of the Rheumatic Diseases, 2011
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendationsArthritis Care & Research, 2008
- Measuring fatigue in rheumatoid arthritis: A systematic review of scales in useArthritis Care & Research, 2007
- Patients' perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignoredArthritis Care & Research, 2005
- Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI)Arthritis & Rheumatism, 2003
- Quality of life profiles in the first years of rheumatoid arthritis: Results from the EURIDISS longitudinal studyArthritis & Rheumatism, 2001
- The Visual Analog Scale in the Immediate Postoperative PeriodAnesthesia & Analgesia, 1998
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992